国际检验医学杂志
國際檢驗醫學雜誌
국제검험의학잡지
INTERNATIONAL JOURNAL OF LABORATORY MEDICINE
2015年
4期
466-469
,共4页
细菌耐药性%趋势观察%平谷地区
細菌耐藥性%趨勢觀察%平穀地區
세균내약성%추세관찰%평곡지구
antibiotic resistance%trend observation%Pinggu area
目的：调查平谷地区2011～2013年临床分离病原菌的耐药情况，指导临床合理使用抗菌药物。方法收集该院2011～2013年临床分离病原菌，将所有分离的病原菌全部鉴定到种并进行药敏试验，同一患者、同一部位的感染菌只选取首次分离株，数据审核后录入 WHONET5．6软件，数据分析依据美国临床实验室标准化协会文件 M100-S22标准。结果2011～2013年临床分离病原菌共5794株。2011年1600株、2012年2234株、2013年 1 960株。耐甲氧西林金黄色葡萄球菌（MRSA）检出率各年度分别为63．50％、65．00％、65．30％，未发现对万古霉素和利奈唑胺耐药的葡萄球菌。肠球菌耐药率：替考拉宁小于5％，利奈唑胺小于2．4％，万古霉素小于21．1％。大肠埃希菌、肺炎克雷伯菌对亚胺培南、美罗培南耐药率均小于1．3％。各年度鲍曼不动杆菌对亚胺培南耐药率分别为34．6％、26．9％、29．3％。铜绿假单胞菌对亚胺培南、美罗培南、头孢哌酮／舒巴坦、哌拉西林／他唑巴坦耐药率低于全国平均水平，未发现对多黏菌素 B 耐药的菌株。嗜麦芽窄食单胞菌对头孢他啶和米诺环素全部敏感。结论平谷地区细菌耐药性数据存在地区特异性，与2011年度全国细菌耐药监测报告的数据存在差异。MRSA 检出率，肠球菌对利奈唑胺和万古霉素的耐药率，大肠埃希菌、肺炎克雷伯菌、阴沟肠杆菌对亚胺培南、美罗培南的耐药率呈逐年上升趋势。鲍曼不动杆菌、铜绿假单胞菌耐药率低于全国平均水平。
目的：調查平穀地區2011～2013年臨床分離病原菌的耐藥情況，指導臨床閤理使用抗菌藥物。方法收集該院2011～2013年臨床分離病原菌，將所有分離的病原菌全部鑒定到種併進行藥敏試驗，同一患者、同一部位的感染菌隻選取首次分離株，數據審覈後錄入 WHONET5．6軟件，數據分析依據美國臨床實驗室標準化協會文件 M100-S22標準。結果2011～2013年臨床分離病原菌共5794株。2011年1600株、2012年2234株、2013年 1 960株。耐甲氧西林金黃色葡萄毬菌（MRSA）檢齣率各年度分彆為63．50％、65．00％、65．30％，未髮現對萬古黴素和利奈唑胺耐藥的葡萄毬菌。腸毬菌耐藥率：替攷拉寧小于5％，利奈唑胺小于2．4％，萬古黴素小于21．1％。大腸埃希菌、肺炎剋雷伯菌對亞胺培南、美囉培南耐藥率均小于1．3％。各年度鮑曼不動桿菌對亞胺培南耐藥率分彆為34．6％、26．9％、29．3％。銅綠假單胞菌對亞胺培南、美囉培南、頭孢哌酮／舒巴坦、哌拉西林／他唑巴坦耐藥率低于全國平均水平，未髮現對多黏菌素 B 耐藥的菌株。嗜麥芽窄食單胞菌對頭孢他啶和米諾環素全部敏感。結論平穀地區細菌耐藥性數據存在地區特異性，與2011年度全國細菌耐藥鑑測報告的數據存在差異。MRSA 檢齣率，腸毬菌對利奈唑胺和萬古黴素的耐藥率，大腸埃希菌、肺炎剋雷伯菌、陰溝腸桿菌對亞胺培南、美囉培南的耐藥率呈逐年上升趨勢。鮑曼不動桿菌、銅綠假單胞菌耐藥率低于全國平均水平。
목적：조사평곡지구2011～2013년림상분리병원균적내약정황，지도림상합리사용항균약물。방법수집해원2011～2013년림상분리병원균，장소유분리적병원균전부감정도충병진행약민시험，동일환자、동일부위적감염균지선취수차분리주，수거심핵후록입 WHONET5．6연건，수거분석의거미국림상실험실표준화협회문건 M100-S22표준。결과2011～2013년림상분리병원균공5794주。2011년1600주、2012년2234주、2013년 1 960주。내갑양서림금황색포도구균（MRSA）검출솔각년도분별위63．50％、65．00％、65．30％，미발현대만고매소화리내서알내약적포도구균。장구균내약솔：체고랍저소우5％，리내서알소우2．4％，만고매소소우21．1％。대장애희균、폐염극뢰백균대아알배남、미라배남내약솔균소우1．3％。각년도포만불동간균대아알배남내약솔분별위34．6％、26．9％、29．3％。동록가단포균대아알배남、미라배남、두포고동／서파탄、고랍서림／타서파탄내약솔저우전국평균수평，미발현대다점균소 B 내약적균주。기맥아착식단포균대두포타정화미낙배소전부민감。결론평곡지구세균내약성수거존재지구특이성，여2011년도전국세균내약감측보고적수거존재차이。MRSA 검출솔，장구균대리내서알화만고매소적내약솔，대장애희균、폐염극뢰백균、음구장간균대아알배남、미라배남적내약솔정축년상승추세。포만불동간균、동록가단포균내약솔저우전국평균수평。
Objective To investigate the drug resistance of clinical isolates in Pinggu area from 2011 to 2013,and guide clinical rational use of antibiotics.Methods Isolates from 2011 to 2013 in the hospital were collected and identified to species.Antibiotic susceptibility test were performed.For the infection with the same position and the same patient,only the first isolate was included. WHONET5.6 data analysis software was used for data auditing and inputing,the USA CLSI M100-S22 standard were refered to. Results Total of 5 794 strains of clinically isolated pathogenic bacteria were collected from 2011 to 2013,1 600 strains in 2011, 2 234 strains in 2012,1 960 strains In 2013.The detection rate of MRSA in each year from 2011 to 2013 were 63.50%,65.00%, 65.30% respectively.No vancomycin and linezolid-resistant Staphylococcus aureus was found.The resistance rate of Enterococcus to teicoplanin was <5%,to Linezolid <2.4% and to vancomycin <21.1%.The resistance rates of Escherichia coli and Klebsiella pneumoniae to imipenem and meropenem were both < 1.3%.The annual resistance rates of Acinetobacter bauman to imipenem were 34.6%,26.9%,29.3% respectively.Resistance rates of Pseudomonas aeruginosa to imipenem,meropenem,cefoperazone/shu-batan,piperacillin/tazobactam were lower than the national average.No polymyxin B resistance isolate was found.Stenotroph-omonas maltophilia were sensitive to ceftazidime and minocycline.Conclusion The antibiotic resistance rate data in Pinggu exhibits area specificity,which was different from the national antimicrobial resistance monitoring data in 2011.Detection rate of MRSA,re-sistance rate of enterococci to linezolid and vancomycin,Escherichia coli,Klebsiella pneumoniae,Enterobacter cloacae to imipenem, meropenem are increasing year by year.The resistance rates of Acinetobacter bauman and Pseudomonas aeruginosa are lower than the national average rate.
